Aytu Biopharma (AYTU) Assets Average (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Assets Average data on file, last reported at $116.8 million in Q1 2026.

• Assets Average for Q1 2026 came in at $116.8 million, down 2.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.8 million (down 2.8% YoY), and the FY2025 annual result was $121.1 million, down 4.83% from the prior year.
• Assets Average fell to $116.8 million in Q1 2026 per AYTU's latest filing, from $123.5 million in the prior quarter.
• Over five years, Assets Average peaked at $196.3 million in Q1 2022 and troughed at $116.0 million in Q4 2024.
• A 5-year average of $134.6 million and a median of $130.1 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average tumbled 41.71% in 2022, then gained 6.51% in 2025.
• A 5-year view of Assets Average shows it stood at $145.7 million in 2022, then slipped by 9.37% to $132.1 million in 2023, then retreated by 12.14% to $116.0 million in 2024, then rose by 6.43% to $123.5 million in 2025, then retreated by 5.38% to $116.8 million in 2026.
• Business Quant data shows AYTU's Assets Average at $116.8 million in Q1 2026, $123.5 million in Q4 2025, and $124.6 million in Q3 2025.